US20180290977A1 - Kdm4 inhibitors - Google Patents

Kdm4 inhibitors Download PDF

Info

Publication number
US20180290977A1
US20180290977A1 US15/936,811 US201815936811A US2018290977A1 US 20180290977 A1 US20180290977 A1 US 20180290977A1 US 201815936811 A US201815936811 A US 201815936811A US 2018290977 A1 US2018290977 A1 US 2018290977A1
Authority
US
United States
Prior art keywords
methyl
amino
compound
kdm4
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/936,811
Other languages
English (en)
Inventor
Roland Schule
Eric Metzger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Ludwigs Universitaet Freiburg
Celgene Quanticel Research Inc
Original Assignee
Albert Ludwigs Universitaet Freiburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Ludwigs Universitaet Freiburg filed Critical Albert Ludwigs Universitaet Freiburg
Priority to US15/936,811 priority Critical patent/US20180290977A1/en
Publication of US20180290977A1 publication Critical patent/US20180290977A1/en
Assigned to CELGENE QUANTICEL RESEARCH, INC., ALBERT-LUDWIGS-UNIVERSITY FREIBURG reassignment CELGENE QUANTICEL RESEARCH, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SCHÜLE, Roland, METZGER, ERIC
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
US15/936,811 2017-03-30 2018-03-27 Kdm4 inhibitors Abandoned US20180290977A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/936,811 US20180290977A1 (en) 2017-03-30 2018-03-27 Kdm4 inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762478785P 2017-03-30 2017-03-30
US201762513875P 2017-06-01 2017-06-01
US15/936,811 US20180290977A1 (en) 2017-03-30 2018-03-27 Kdm4 inhibitors

Publications (1)

Publication Number Publication Date
US20180290977A1 true US20180290977A1 (en) 2018-10-11

Family

ID=63678220

Family Applications (3)

Application Number Title Priority Date Filing Date
US15/936,811 Abandoned US20180290977A1 (en) 2017-03-30 2018-03-27 Kdm4 inhibitors
US16/498,714 Abandoned US20200039938A1 (en) 2017-03-30 2018-03-27 Kdm4 inhibitors
US17/749,233 Pending US20240076271A1 (en) 2017-03-30 2022-05-20 Kdm4 inhibitors

Family Applications After (2)

Application Number Title Priority Date Filing Date
US16/498,714 Abandoned US20200039938A1 (en) 2017-03-30 2018-03-27 Kdm4 inhibitors
US17/749,233 Pending US20240076271A1 (en) 2017-03-30 2022-05-20 Kdm4 inhibitors

Country Status (5)

Country Link
US (3) US20180290977A1 (ja)
EP (1) EP3600301A4 (ja)
JP (1) JP7442439B2 (ja)
TW (1) TWI814723B (ja)
WO (1) WO2018183370A2 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023023112A1 (en) * 2021-08-18 2023-02-23 Celgene Corporation Process for preparing histone demethylase inhibitors

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2862648T3 (es) * 2014-06-25 2021-10-07 Celgene Quanticel Res Inc Inhibidores de la histona desmetilasa
CN113876953B (zh) * 2020-07-02 2022-12-09 中国科学院上海营养与健康研究所 新型细胞衰老干预靶点及其在化疗抗癌中的靶向应用
WO2023122221A1 (en) * 2021-12-23 2023-06-29 Tachyon Therapeutics, Inc. Pharmaceutical formulations comprising 3-({[(4r)-7-{methyl[4-(propan-2-yl)phenyl]amino}-3,4-dihydro-2h-l-benzopyran-4-yl]methyl}amino)pyridine-4-carboxylic acid
WO2024064734A1 (en) * 2022-09-21 2024-03-28 Celgene Corporation Crystalline forms of 3-({[(4r)-7-{methyl[4-(propan-2- yl)phenyl]amino}-3,4-dihydro-2h-l-benzopyran-4- yl]methyl}amino)pyridine-4-carboxylic acid l-lysine salt, a histone demethylase inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150376169A1 (en) * 2014-06-25 2015-12-31 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
ES2718495T3 (es) * 2012-12-21 2019-07-02 Celgene Quanticel Res Inc Inhibidores de la histona desmetilasa
PL3640241T3 (pl) 2013-10-18 2022-12-05 Celgene Quanticel Research, Inc. Inhibitory bromodomeny
US9890434B2 (en) * 2014-03-19 2018-02-13 National Tsing Hua University Method for identifying compound for inhibiting an activity of a histone lysine demethylase
RS62874B1 (sr) 2014-05-01 2022-02-28 Celgene Quanticel Research Inc Inhibitori lizin specifične demetilaze-1
CN108698997A (zh) 2015-12-28 2018-10-23 赛尔基因昆蒂赛尔研究公司 组蛋白脱甲基酶抑制剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150376169A1 (en) * 2014-06-25 2015-12-31 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023023112A1 (en) * 2021-08-18 2023-02-23 Celgene Corporation Process for preparing histone demethylase inhibitors

Also Published As

Publication number Publication date
JP2020515645A (ja) 2020-05-28
TW201840537A (zh) 2018-11-16
EP3600301A2 (en) 2020-02-05
WO2018183370A2 (en) 2018-10-04
JP7442439B2 (ja) 2024-03-04
US20200039938A1 (en) 2020-02-06
US20240076271A1 (en) 2024-03-07
TWI814723B (zh) 2023-09-11
EP3600301A4 (en) 2020-08-12
WO2018183370A3 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
US20240076271A1 (en) Kdm4 inhibitors
US10537561B2 (en) CSF-1R inhibitors for treatment of brain tumors
US10959984B2 (en) Methods for treating cancer with RORγ inhibitors
CN107949387B (zh) 用谷氨酰胺酶抑制剂治疗肺癌
US20230181489A1 (en) Combination therapies targeting mitochondrial biogenesis for cancer therapy
US20100150844A1 (en) Use of 8-quinolinol and its analogs to target cancer stem cells
Zhang et al. Retracted: long noncoding RNA MT1JP inhibits proliferation, invasion, and migration while promoting apoptosis of glioma cells through the activation of PTEN/Akt signaling pathway
KR20220123064A (ko) Cdk12/13 억제제에 의한 암 치료
US10512642B2 (en) Therapeutic targeting of myeloproliferative neoplasms by DUSP1 inhibition
EP2397149A1 (en) Pharmaceutical preparation comprising actinomycin D for the treatment of B-CLL in patients having del(17p)
US11427543B2 (en) Compounds for targeting cancer stem cells
WO2012078982A2 (en) Xzh-5 inhibits constitutive and interleukin-6-induced stat3 phosphorylation in human hepatocellular carcinoma cells
WO2021011800A1 (en) Method of treating neoplastic diseases with a cdc42-specific inhibitor
US10213449B2 (en) Compositions and methods for treating medulloblastoma
Yang MDM2 Degradation as a Novel and Efficacious Cancer Therapy
Bauckman Characterization of Iron Response in Gynecological Cell Lines
TW201208668A (en) Compounds for the treatment of cancer and its application
NZ617243B2 (en) Combinations of akt and mek inhibitor compounds, and methods of use

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: CELGENE QUANTICEL RESEARCH, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHUELE, ROLAND;METZGER, ERIC;SIGNING DATES FROM 20231025 TO 20231102;REEL/FRAME:065496/0055

Owner name: ALBERT-LUDWIGS-UNIVERSITY FREIBURG, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHUELE, ROLAND;METZGER, ERIC;SIGNING DATES FROM 20231025 TO 20231102;REEL/FRAME:065496/0055